RVL Pharmaceuticals Focuses on Scaling Upneeq as Market Momentum Builds
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
Data presented at the Science of Skin Summit indicate topical regimens and treatments yield visible improvements in laxity, crepiness, and perceived age among individuals taking GLP-1 therapies.